Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma Save

Date Added
December 20th, 2016
PRO Number
Pro00061291
Researcher
Amarendra Neppalli

Silhouette
Keywords
Cancer/Myeloma
Summary

This study is for adult patients who have high risk myeloma (MM), a cancer of the plasma cells that begins in their bone marro OR their MM returned after an autologous transplant. The study is being done to learn if maintenance treatment (chemotherapy) works better to control your disease than placebo.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma Save

Date Added
September 8th, 2015
PRO Number
Pro00046355
Researcher
Amarendra Neppalli

Silhouette
Keywords
Cancer, Drug Studies, Men's Health, Women's Health
Summary

This study is for patients that have been diagnosed with multiple myeloma. The investigational drug in this study is carfilzomib. The purpose of this study is to find out more about carfilzomib in people with multiple myeloma, a cancer that affects how normal blood cells grow and work. Participants can expect to be in this study for about 2.5 years (30 months), including a maximum of about 1.5 years (18 months) of study drug administration as well as about 1 year of follow-up visits.

Institution
MUSC
Recruitment Contact
Shanta Salzer
843-792-1463
salzers@musc.edu

A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus Host-Disease Save

Date Added
March 17th, 2015
PRO Number
Pro00041659
Researcher
Amarendra Neppalli

Silhouette
Keywords
Cancer/Leukemia
Summary

The purpose of this study is to compare three different combinations of treatment plans to see whether one or more of them are better than a standard transplant procedure. The procedures being studied have the objective to reduce the occurrence of chronic GVHD.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Change_preferences

-- OR --

Create_login